Conditions: Postmenopausal Osteoporosis
Keywords: Postmenopausal Osteoporosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 436
Healthy volunteers: no

Brief summary:
The primary objective of the study was to evaluate the effect of 12 months of treatment with romosozumab compared with teriparatide on total hip bone mineral density (BMD) in postmenopausal women with osteoporosis who were previously treated with bisphosphonate therapy.

Detailed description:

Arms:
arm 1: Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months. arm 2: Participants received 20 μg/day teriparatide administered by subcutaneous injection for 12 months.

Interventions: intervention 1: Romozosumab intervention 2: Teriparatide
Intervention descriptions: intervention 1: Administered by subcutaneous injection once a month. intervention 2: Administered by subcutaneous injection once a day.

Protocol document: